long intergenic non-protein coding RNA 2626Genealiases: []
Q-omics provides the consensus-scored LINC02626 profile across patient tissues and cancer cell-line models. LINC02626 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC02626 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, LINC02626 RNA expression shows 8,749 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LIHC, and UVM as cancer lineages where LINC02626 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02626 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02626 survival associations across molecular data types. LINC02626 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02626 RNA expression–survival associations across cancer types. High LINC02626 expression shows unfavorable associations in KIRC, ACC and THCA, but favorable associations in MESO, READ and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for LINC02626 RNA expression.
This table summarizes LINC02626 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02626. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02626 shows higher tumor expression in LIHC, HNSC, BLCA, KIRP, UCEC and LUSC. The LIHC box plot shows higher LINC02626 RNA expression in tumor versus normal tissue (log2 FC = +0.134, t-test p < 0.001).
This table shows molecular features associated with LINC02626 in patient tissues and cancer cell lines. In patient samples, LINC02626 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
